Literature DB >> 21186794

α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

Martina Bazzaro1, Ravi K Anchoori, Mohana Krishna R Mudiam, Olga Issaenko, Srinivas Kumar, Balasubramanyam Karanam, Zhenhua Lin, Rachel Isaksson Vogel, Riccardo Gavioli, Federica Destro, Valeria Ferretti, Richard B S Roden, Saeed R Khan.   

Abstract

Proteasome inhibitors have potential for the treatment of cervical cancer. We describe the synthesis and biological characterization of a new series of n class="Chemical">1,3-diphenylpropen-1-one (chalcone) based derivatives lacking the boronic acid moieties of the previously reported chalcone-based proteasome inhibitor 3,5-bis(4-boronic acid benzylidene)-1-methylpiperidin-4-one and bearing a variety of amino acid substitutions on the amino group of the 4-piperidone. Our lead compound 2 (RA-1) inhibits proteasomal activity and has improved dose-dependent antiproliferative and proapoptotic properties in cervical cancer cells containing human papillomavirus. Further, it induces synergistic killing of cervical cancer cell lines when tested in combination with an FDA approved proteasome inhibitor. Exploration of the potential mechanism of proteasomal inhibition by our lead compound using in silico docking studies suggests that the carbonyl group of its oxopiperidine moiety is susceptible to nucleophilic attack by the γ-hydroxythreonine side chain within the catalytic sites of the proteasome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186794      PMCID: PMC3204583          DOI: 10.1021/jm100589p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.

Authors:  Geetha Achanta; Aneta Modzelewska; Li Feng; Saeed R Khan; Peng Huang
Journal:  Mol Pharmacol       Date:  2006-04-24       Impact factor: 4.436

2.  Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.

Authors:  Michael Groll; Robert Huber
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

3.  Development of lipopeptides for inhibiting 20S proteasomes.

Authors:  Nicolas Basse; David Papapostolou; Maurice Pagano; Michèle Reboud-Ravaux; Elise Bernard; Anne-Sophie Felten; Régis Vanderesse
Journal:  Bioorg Med Chem Lett       Date:  2006-04-21       Impact factor: 2.823

4.  Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation.

Authors:  Michael Groll; Oleg V Larionov; Robert Huber; Armin de Meijere
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

5.  Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors.

Authors:  M Marastoni; A Baldisserotto; C Trapella; R Gavioli; R Tomatis
Journal:  Eur J Med Chem       Date:  2006-05-18       Impact factor: 6.514

6.  Human papillomavirus: E6 and E7 oncogenes.

Authors:  Gaëlle Boulet; Caroline Horvath; Davy Vanden Broeck; Shaira Sahebali; Johannes Bogers
Journal:  Int J Biochem Cell Biol       Date:  2007-07-19       Impact factor: 5.085

7.  Vinyl ester-based cyclic peptide proteasome inhibitors.

Authors:  Anna Baldisserotto; Mauro Marastoni; Stella Fiorini; Loretta Pretto; Valeria Ferretti; Riccardo Gavioli; Roberto Tomatis
Journal:  Bioorg Med Chem Lett       Date:  2008-02-10       Impact factor: 2.823

8.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Qing Chen; Peter M Voorhees; John S Strader; Kevin D Shenk; Congcong M Sun; Susan D Demo; Mark K Bennett; Fijs W B van Leeuwen; Asher A Chanan-Khan; Robert Z Orlowski
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

Review 9.  Targeting proteasomes as therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 10.  Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.

Authors:  Mako Narisawa-Saito; Tohru Kiyono
Journal:  Cancer Sci       Date:  2007-07-23       Impact factor: 6.716

View more
  16 in total

1.  RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.

Authors:  Raffaele Hellweg; Ashley Mooneyham; Zenas Chang; Mihir Shetty; Edith Emmings; Yoshie Iizuka; Christopher Clark; Timothy Starr; Juan H Abrahante; Florian Schütz; Gottfried Konecny; Peter Argenta; Martina Bazzaro
Journal:  Horm Cancer       Date:  2018-06-27       Impact factor: 3.869

Review 2.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

3.  Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

Authors:  Paige Dickson; Daniel Abegg; Ekaterina Vinogradova; Junichiro Takaya; Hongchan An; Scott Simanski; Benjamin F Cravatt; Alexander Adibekian; Thomas Kodadek
Journal:  Cell Chem Biol       Date:  2020-08-27       Impact factor: 8.116

4.  A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.

Authors:  Ravi K Anchoori; Balasubramanyam Karanam; Shiwen Peng; Joshua W Wang; Rosie Jiang; Toshihiko Tanno; Robert Z Orlowski; William Matsui; Ming Zhao; Michelle A Rudek; Chien-fu Hung; Xiang Chen; Kylie J Walters; Richard B S Roden
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

5.  Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.

Authors:  Olga A Issaenko; Alexander Yu Amerik
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

Review 6.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

7.  (E)-4-aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiproliferative activity and inhibition of tubulin polymerization.

Authors:  Maja D Vitorović-Todorović; Aleksandra Erić-Nikolić; Branka Kolundžija; Ernest Hamel; Slavica Ristić; Ivan O Juranić; Branko J Drakulić
Journal:  Eur J Med Chem       Date:  2013-01-11       Impact factor: 6.514

8.  Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.

Authors:  Kathleen Coughlin; Ravi Anchoori; Yoshie Iizuka; Joyce Meints; Lauren MacNeill; Rachel Isaksson Vogel; Robert Z Orlowski; Michael K Lee; Richard B S Roden; Martina Bazzaro
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

9.  Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.

Authors:  Ravi K Anchoori; Saeed R Khan; Thanasak Sueblinvong; Alicia Felthauser; Yoshie Iizuka; Riccardo Gavioli; Federica Destro; Rachel Isaksson Vogel; Shiwen Peng; Richard B S Roden; Martina Bazzaro
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

10.  The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.

Authors:  Xin Wang; Magdalena Mazurkiewicz; Ellin-Kristina Hillert; Maria Hägg Olofsson; Stefan Pierrou; Per Hillertz; Joachim Gullbo; Karthik Selvaraju; Aneel Paulus; Sharoon Akhtar; Felicitas Bossler; Asher Chanan Khan; Stig Linder; Padraig D'Arcy
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.